Literature DB >> 19712713

Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.

Niels Hagenaars1, Rolf J Verheul, Imke Mooren, Pascal H J L F de Jong, Enrico Mastrobattista, Harrie L Glansbeek, Jacco G M Heldens, Han van den Bosch, Wim E Hennink, Wim Jiskoot.   

Abstract

The aim of this study was to assess the influence of structural properties of N,N,N-trimethyl chitosan (TMC) on its adjuvanticity. Therefore, TMCs with varying degrees of quaternization (DQ, 22-86%), O-methylation (DOM, 0-76%) and acetylation (DAc 9-54%) were formulated with whole inactivated influenza virus (WIV). The formulations were characterized physicochemically and evaluated for their immunogenicity in an intranasal (i.n.) vaccination/challenge study in mice. Simple mixing of the TMCs with WIV at a 1:1 (w/w) ratio resulted in comparable positively charged nanoparticles, indicating coating of WIV with TMC. The amount of free TMC in solution was comparable for all TMC-WIV formulations. After i.n. immunization of mice with WIV and TMC-WIV on days 0 and 21, all TMC-WIV formulations induced stronger total IgG, IgG1 and IgG2a/c responses than WIV alone, except WIV formulated with reacetylated TMC with a DAc of 54% and a DQ of 44% (TMC-RA44). No significant differences in antibody titers were observed for TMCs that varied in DQ or DOM, indicating that these structural characteristics play a minor role in their adjuvant properties. TMC with a DQ of 56% (TMC56) formulated with WIV at a ratio of 5:1 (w/w) resulted in significantly lower IgG2a/c:IgG1 ratios compared to TMC56 mixed in ratios of 0.2:1 and 1:1, implying a shift towards a Th2 type immune response. Challenge of vaccinated mice with aerosolized virus demonstrated protection for all TMC-WIV formulations with the exception of TMC-RA44-WIV. In conclusion, formulating WIV with TMCs strongly enhances the immunogenicity and induces protection against viral challenge in mice after i.n. vaccination. The adjuvant properties of TMCs as i.n. adjuvant are strongly decreased by reacetylation of TMC, whereas the DQ and DOM hardly affect the adjuvanticity of TMC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19712713     DOI: 10.1016/j.jconrel.2009.08.018

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  8 in total

1.  Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants.

Authors:  Yuhong Jiang; Man Li; Zhirong Zhang; Tao Gong; Xun Sun
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

2.  Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines.

Authors:  Caitlin D Lemke; Jessica B Graham; Sean M Geary; Gideon Zamba; David M Lubaroff; Aliasger K Salem
Journal:  Mol Pharm       Date:  2011-08-09       Impact factor: 4.939

3.  Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.

Authors:  Zachary R Sia; Matthew S Miller; Jonathan F Lovell
Journal:  Mol Pharm       Date:  2020-08-17       Impact factor: 4.939

4.  Responses of primary human nasal epithelial cells to EDIII-DENV stimulation: the first step to intranasal dengue vaccination.

Authors:  Nattika Nantachit; Panya Sunintaboon; Sukathida Ubol
Journal:  Virol J       Date:  2016-08-18       Impact factor: 4.099

Review 5.  Novel application of trimethyl chitosan as an adjuvant in vaccine delivery.

Authors:  Anshu Malik; Manish Gupta; Vatika Gupta; Himanshu Gogoi; Rakesh Bhatnagar
Journal:  Int J Nanomedicine       Date:  2018-11-23

6.  The dry powder formulation of mixed cross-linked dextran microspheres and tetanus toxoid-loaded trimethyl chitosan nanospheres as a potent adjuvant for nasal delivery system.

Authors:  Mona Kabiri; Haleh Bolourian; Solmaz Dehghan; Mohsen Tafaghodi
Journal:  Iran J Basic Med Sci       Date:  2021-01       Impact factor: 2.699

Review 7.  Chitosan-Based Nanoparticles Against Viral Infections.

Authors:  Homa Boroumand; Fereshteh Badie; Samaneh Mazaheri; Zeynab Sadat Seyedi; Javid Sadri Nahand; Majid Nejati; Hossein Bannazadeh Baghi; Mohammad Abbasi-Kolli; Bita Badehnoosh; Maryam Ghandali; Michael R Hamblin; Hamed Mirzaei
Journal:  Front Cell Infect Microbiol       Date:  2021-03-17       Impact factor: 5.293

8.  Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax.

Authors:  Anshu Malik; Manish Gupta; Rajesh Mani; Himanshu Gogoi; Rakesh Bhatnagar
Journal:  Front Immunol       Date:  2018-03-20       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.